Compare Amylx Pharmaceuticals Inc (AMLX) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.37 (market cap $1.98B), while Manulife Financial Corporation trades at $41.05 (market cap $68.50B). The key difference: Manulife Financial Corporation is far larger — about 34.6× Amylx Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MFC | |
|---|---|---|
Market Cap | $1.98B | $68.50B |
Sector | Health | Financials |
52-Week High | $18.70 | $41.49 |
52-Week Low | $7.64 | $29.90 |
Enterprise Value | $1.70B | $65.07B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Manulife Financial (MFC) trades at $41.29, down 0.48% with a bullish technical outlook. The stock shows solid fundamentals with revenue growth to $53.01B in 2025 and net income of $5.78B, though Q1 2026 earnings missed expectations. Analyst consensus is strongly bullish with 57% buy ratings, supported by positive AI developments and dividend payments.
MFC presents a compelling investment case with strong profitability metrics (ROE 13.14%) and reasonable valuation (P/E 16.89). Key risks include regulatory scrutiny in Hong Kong and wealth management outflows. The company's AI leadership and Asia growth provide upside potential, though investors should monitor execution on recent strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
